{"prompt": "['Fully licensed psychiatrists who are also licensed buprenorphine/naloxone', \"providers who work at the Cambridge Health Alliance's Outpatient Addiction\", 'Services will initiate and monitor Epclusa treatment with training and ongoing', 'mentoring by Dr. Amy Colson, the Sponsor-Investigator. Initial training prior to', 'enrolling subjects will address interpretation of HCV diagnostic tests, assessment', 'of liver fibrosis, selection of patients for HCV treatment,', 'administration/monitoring of Epclusa therapy, and post-therapy assessment of', 'treatment effectiveness. The Sponsor-Investigator will conduct weekly', 'telephone consultation and mentorship throughout the course of the study.', \"The psychiatrists' level of comfort with providing care for hepatitis C infection\", 'will be determined by a questionnaire administered before and at the', 'completion of their training session and after 4 months of prescribing HCV', 'therapy to study participants.', 'This study will be conducted in accordance with the guidelines of Good Clinical Practices (GCPs) including', 'archiving of essential documents.', 'CRI 15-05 Protocol 13SEP2017', 'Page 9']['2 Glossary of Abbreviations and Definition of Terms', 'AE', 'adverse event', 'ALT', 'alanine aminotransferase (also SGPT)', 'AST', 'aspartate aminotransferase (also SGOT)', 'BID', 'twice a day', 'CD4', 'Cluster of differentiation 4', 'CI', 'Confidence Interval', 'CRF', 'case report form(s)', 'CRI', 'Community Research Initiative of New England', 'CSR', 'clinical study report', 'dL', 'Deciliter', 'DSPH', 'Drug Safety and Public Health', 'ECG', 'Electrocardiogram', 'eCRF', 'Electronic case report form(s)', 'EOT', 'End of Treatment', 'ET', 'Early Termination', 'EU', 'European Union', 'FACIT-F', 'Functional Assessment of Chronic Illness Therapy-Fatigue', 'FDA', '(United States) Food and Drug Administration', 'FDC', 'Fixed dose combination', 'FEV1', 'forced expiratory volume in one second', 'GCP', 'Good Clinical Practice (Guidelines)', 'GCSF', 'Granulocyte colony stimulating factor', 'GGT', 'gamma-glutamyl transferase', 'GSI', 'Gilead Sciences, Inc.', 'Hb', 'Hemoglobin', 'HbA1c', 'Hemoglobin A1c', 'HBV', 'Hepatitis B virus', 'HCV', 'Hepatitis C virus', 'ICH', 'International Conference on Harmonisation', 'CRI 15-05 Protocol 13SEP2017', 'Page 10']['IEC', 'independent ethics committee', 'IND', 'Investigational New Drug (Application)', 'INR', 'International Normalized Ratio of prothrombin time', 'IRB', 'institutional review board', 'IUD', 'intrauterine device', 'IU', 'international units', 'IV', 'Intravenous', 'Kg', 'Kilogram', 'L', 'Liter', 'LDL', 'low-density lipoprotein', 'LLN', 'lower limit of the normal range', 'LLOQ', 'Lower limit of quantification', 'LLT', 'Lower-Level Term', 'MCV', 'mean corpuscular volume or mean cell volume', 'Mg', 'Milligram', 'Mm', 'Millimeter', 'mL', 'Milliliter', 'Min', 'Minute', 'mmHg', 'millimeters mercury', 'P-gp', 'P-glycoprotein', 'PG', 'Pharmacogenomic', 'PO', 'by mouth', 'QD', 'once daily (use only in tablets)', 'PK', 'Pharmacokinetic', 'PT', 'preferred term or prothrombin time', 'RBC', 'red blood cell count', 'RNA', 'ribonucleic acid', 'RVR', 'rapid virologic response', 'SADR', 'Serious adverse drug reaction', 'SAE', 'serious adverse event', 'CRI 15-05 Protocol 13SEP2017', 'Page 11']\n\n###\n\n", "completion": "END"}